Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Northwest Biotherapeutics (OTC.BB:NWBO) today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal type of brain cancer.  

The four recruiting centers are located in New York (University of Rochester), Ohio (University Hospitals of Cleveland), Michigan (Henry Ford Health System) and Minnesota (Virginia Piper Cancer Center of the University of Minnesota).  

Another eight medical centers, spread over multiple other states across the country, have been making preparations for additional enrollment in the ongoing GBM trial.  At least four of these eight additional sites are expected to begin or resume recruiting and screening for such enrollment during this calendar quarter.

To date, 33 patients have already been enrolled in this ongoing 240-patient GBM brain cancer trial and its information arm, and have been proceeding through the treatment regimen and follow-up.  

In prior clinical trials of DCVax® immune therapy for GBM brain cancer, the results were striking:  the patients who received DCVax® showed a median survival of 3 years, compared with median survival of only 14.6 months with standard of care today (surgery, radiation and chemotherapy).  In addition, the patients treated with DCVax® did not have their tumor recur for approximately 2 years, on average, as compared with tumor recurrence in just 7 months with standard of care today.  Moreover, the patients treated with DCVax® did not experience any toxic side effects, in stark contrast to chemotherapies.  

"We are pleased to have medical centers spread across the U.S. which are ramping up additional enrollment into our ongoing GBM brain cancer clinical trial," said Dr. Alton Boynton, CEO of NWBT.  "This will help patients participate in the trial without having to travel too far, and it will also help us accelerate the overall enrollment required for completion of the trial."

SOURCE Northwest Biotherapeutics, Inc.